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Abstract
The study was performed to evaluate the expression of some proapoptotic genes for early prognosis of ovarian
cancer. Twenty-four fresh frozen ovarian tumor and 9 normal ones were considered for real-time polymerase
chain reaction. CASP8 and BAD genes were decreased in tumoral tissues. Downregulation of CASP8 and BAD
genes in ovarian cancer may be an important cause for ovarian cancer.
Background: Ovarian cancer as the most lethal gynecologic malignancy in women is poorly detected during early
stages of carcinogenesis. Therefore, there is an emergent need to look for speciﬁc and sensitive biomarkers for early
diagnosis of ovarian cancer.Materials and Methods: In this study, we performed real-time polymerase chain reaction
(PCR) to evaluate the expression of six proapoptotic genes, CASP8, BAK, APAF1, BAX, BID, and BAD, which contain
CpG islands in their promoter regions. Afterward, the signiﬁcantly downregulated genes were investigated by HpaII-
PCR and methylation-speciﬁc PCR (MSP) to determine the methylation status between tumoral and adjacent normal
tissues. Results: The real-time PCR results in 24 tumoral and 9 normal adjacent tissues showed decreased expression
of CASP8 and BAD genes in tumoral relative to normal samples. Furthermore, the methylation analysis showed no
signiﬁcant methylation between tumoral and normal samples. Conclusion: Taken together, this could be concluded
that downregulation of CASP8 and BAD genes in ovarian cancer may be as important causes for ovarian cancer
carcinogenesis via inducing resistance to apoptosis; however, the downregulations are not due to promoter
hypermethylation.
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Ovarian cancer is the most lethal gynecologic cancer and the
seventh leading cause of cancer related death in females worldwide.1
The epithelial ovarian cancer (EOC) that makes up to 90% of all
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Clinical Ovarian and Other Gynecologic Cancer December 2014mesothelium that covers the surface of the ovary. Because of the lack
of either speciﬁc symptoms or early detection strategies, ovarian
cancer is the most deadly malignancy in women.2 More than 70%
of patients with ovarian cancer are being diagnosed at stages III and
IV, and 20% to 35 % of them will have 5 year survival rates,
whereas in the case of detection in stage I, up to 90% of patients can
be cured with chemotherapy.2,3
Currently, transvaginal sonography and biochemical serum
markers such as CA125 have been investigated for early detection of
ovarian cancer.4 However, the high rate of false positives makes the
CA125 an unsuitable biomarker for EOC diagnosis.5 In addition,
from medical surgery perspective, there is growing evidence about
laparoscopic surgery beneﬁts for management of early stage ovarian
cancer that by overcoming some limitations can be considered as a
new and beneﬁcial technique for treatment of ovarian cancer but
with much less postsurgical complications.6 Interestingly, long term
follow up after ovarian cancer laparoscopy has revealed a promising
result that would be a new era for ovarian cancer therapy.72212-9553/$ - see frontmatter ª 2015 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2014.12.004
Table 1 Clinicopathologic Features of Study Samples
Clinicopathologic Features Number (%)
Age (years)
50 15 (62.5)
>50 9 (37.5)
Site of Primary
Ovarian 24 (100)
Other 0 (0)
Tumor Spreading
Bilateral 7 (29.2)
Unilateral 17 (70.8)
Tumor Size (cm)
10 10 (41.6)
>10 14 (58.4)
Histologic Subtype
Mucinous 4 (16.7)
Serous 14 (58.3)
Clear cell 6 (25)
Grade/Differentiation
G1 G2 6 (25)
G3 G4 7 (29.1)
GX 6 (25)
GB 5 (20.9)Obviously, early detection of ovarian cancer could signiﬁcantly
improve the survival rate of women at risk of developing ovarian
cancer; therefore, ﬁnding the sensitive and speciﬁc biomarkers for
noninvasive diagnosis of this cancer is highly demanded. Many ef
forts have been made for identiﬁcation of molecular biomarkers
which including gene expression variations, proteins, and DNA
methylation markers. DNA methylation as an epigenetic mark
which occurs at CG dinucleotides in CpG islands is considered as
substantial and promising biomarker for early detection of different
cancers including EOC.8 Many genes and markers such as TGFBI,
IFFO1, HIN 1, CHFR, SPARC, THBS2, and RASSF1A have been
reported to be hypermethylated in ovarian cancer.9 15
Cancer as a complex disease that results from genetic and epige
netic modiﬁcations of tumor suppressor genes or oncogenes can be
developed because of alterations of apoptosis signaling pathways.16
The apoptosis or programmed cell death is initiated via 2 extrinsic
and intrinsic pathways that have been proposed to be involved in
different cancers. The extrinsic and intrinsic pathways are triggered
by the death receptors on cell surface (TRAIL R1 and R2, FAS, and/
or TNF a) and mitochondria, respectively.17 These pathways consist
of many factors that have important roles in initiation and progres
sion of apoptosis. Absence or downregulation of the proapoptotic
genes could cause resistance to apoptosis and associated with different
cancers.18 The genes, CASP8, BAK1, APAF1, BID, BAD, and BAX,
are essential factors of cell death, and deregulation of these genes is
involved in different human malignancies and chemoresistance.16,19
These genes have CpG islands in their 50 upstream ﬂanking regions;
thus, they are prone to be methylated and transcriptionally silenced.
Therefore, the aim of this study was to determine the changes in gene
expression of 6 important proapoptotic genes between tumoral and
normal adjacent tissues of ovary and to look for DNA methylation in
the promoter of the genes which were signiﬁcantly downregulated.
Materials and Methods
Patients and Specimens
Twenty four fresh frozen ovarian tumor and 9 normal adjacent
tissues were provided by the Iran National Tumor Bank (INTB)
which is funded by Cancer Institute of Tehran University. The
normal tissues were dissected at least 6 cm away from tumor sites. The
clinical data including histology, patient history, and family history of
all samples were provided by INTB (Table 1). Furthermore, the
informed consents were signed by the patients or close relatives.
DNA/RNA Extraction and cDNA Synthesis
The fresh frozen tissues were grinded in liquid nitrogen using
mortar and pestle and then transferred instantly into lysis buffer of
AllPrep DNA/RNA Mini Kit (Qiagen, Los Angeles, California) for
following extraction based on manufacturer protocol. The quality
and quantity of extracted DNA and RNA were measured via agarose
gel electrophoresis and Biophotometer (Eppendorf, Hamburg,
Germany). The cDNA was synthesized using 500 ng of total RNA
and PrimeScript RT Reagent Kit (Takara Bio Inc, Shiga, Japan)
regarding manufacture protocol.
Real-Time Polymerase Chain Reaction (PCR)
The proapoptotic gene expression levels between normal and
adjacent normal tissues were measured by quantitative real timePCR in a Rotor gene 6000 instrument (Corbett life science, Syd
ney, Australia) using SYBR Premix Ex Taq II (TAKARA, Japan).
The total 20 m reaction volume contained 10 m SYBR Premix, 1 m
cDNA, 1 m of forward and reverse primers, and 8 m ddH2O that
was performed in 2 step real time PCR (95C for 10 seconds and
60C for 35 seconds). Relative gene expression changes between
cDNA samples were determined using Relative expression software
tool 9 (REST 9, Qiagen), in which the GAPDH gene was used as
internal control. The primer sequences for real time PCR were
extracted from PrimerBank Web site (http://pga.mgh.harvard.edu/
primerbank/; Table 2).
HpaII/MspI-PCR
The HpaII methylation sensitive restriction enzyme that has 50
CCGG 30 cutting site in unmethylated cytosine status was per
formed to evaluate the methylation ratios between tumoral and
normal samples. At ﬁrst, 10 mg of extracted DNAs was digested
using HpaII and MspI restriction enzymes separately; then, the
PCR was carried out after digestion. The speciﬁc primer sets for
BAD gene promoter regions were designed, wherein the primers
ﬂank one CCGG site sequence and amplicons have at least one
HpaII/MspI cutting site. The primer sets were designed using
Primer 3 software (http://bioinfo.ut.ee/primer3/), and include: F:
50 CCCACGCTCCTCTCTCCTAT 30 and R: 50 GCTATGGGCG
GAAGTTTTCT 30.
Bisulﬁte Conversion and Methylation-Speciﬁc PCR (MSP)
Sodium bisulﬁte conversion of genomic DNA was carried out
using EpiTect Bisulﬁte Kit (Qiagen, Hilden, Germany). TheClinical Ovarian and Other Gynecologic Cancer December 2014 - 19
Table 2 The Primer Sets for Real-Time Polymerase Chain Reaction
Gene Name Primer Sequence Gene Name Primer Sequence
CASP8 F: AGAGTCTGTGCCCAAATCAAC APAF1 F: AAGGTGGAGTACCACAGAGG
R: GCTGCTTCTCTCTTTGCTGAA R: TCCATGTATGGTGACCCATCC
BID F: CCTTGCTCCGTGATGTCTTTC BAK F: ATGGTCACCTTACCTCTGCAA
R: GTAGGTGCGTAGGTTCTGGT R: TCATAGCGTCGGTTGATGTCG
BAD F: CCCAGAGTTTGAGCCGAGTG GAPDH F: AAGGTGAAGGTCGGAGTCAAC
R: CCCATCCCTTCGTCGTCCT R: GGGGTCATTGATGGCAACAATA
BAX F: CCCGAGAGGTCTTTTTCCGAG
R: CCAGCCCATGATGGTTCTGAT
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20 -human control DNA containing both bisulﬁte converted methyl
ated and unmethylated DNA sets (EpiTect PCR Control DNA Set,
Qiagen, Hilden, Germany) was used for MSP control reactions.
The speciﬁc primer pair for methylated and unmethylated DNA
(Table 3) and PCR condition was extracted from previously pub
lished literature.20
Results
Patient Samples
The samples composed of 24 tumoral, 9 normal adjacent, and 9
normal with no diagnosed cancer. The patients aged between 22
and 71 years (mean ¼ 49), with both unilateral (68%) and bilateral
(32%) tumors. In addition, the tumor samples sizes were ranged
between 4 and 20 cm and different grades and different TNM
pathologic staging (Table 1).
Real-Time PCR Results
The real time PCR was carried out (Table 2), and the results
showed downregulation of BAD gene in 9 tumoral samples relative
to their normal adjacent controls. When we totally compared the
relative expression of the genes between 24 tumoral and 18 normal
tissues (9 normal adjacent samples and 9 normal noncancerous
people), the CASP8 gene showed signiﬁcant decreased expression in
tumoral compared to normal samples (Figure 1).
HpaII/MspI-PCR Result
The PCR after digestion with HpaII and MspI enzymes showed
no signiﬁcant methylation difference between tumoral tissues and
normal samples (Figure 2). In this study, methylated and unme
thylated digested and intact undigested DNAs were used as controls.
MSP Result
The MSP for CASP8 gene promoter methylation (Table 3) was
performed to verify our HpaII/MspI PCR results. The MSP assaysTable 3 Methylation-Speciﬁc Polymerase Chain Reaction
Primer Sets for Methylated and Unmethylated CASP8
Promoter
Primer Sequence
Casp 8 methylated forward TAGGGGATTCGGAGATTGCGA
Casp 8 methylated reverse CGTATATCTACATTCGAAACGA
Casp 8 unmethylated forward TAGGGGATTTGGAGATTGTGA
Casp 8 unmethylated reverse CCATATATCTACATTCAAAACAA
Clinical Ovarian and Other Gynecologic Cancer December 2014conﬁrmed our result and showed no signiﬁcant methylation in tu
mor samples compared to normal samples (Figure 3).
Discussion
Our ﬁndings suggest that downregulation of CASP8 and BAD in
ovarian tumoral versus normal adjacent samples might have possible
roles in ovarian carcinogenesis. These 2 genes have roles in initiation
and regulation of apoptosis. The protein encoded by BAD gene
forms heterodimers with BCL xL and BCL 2 proteins and reversing
their death repressor activity and therefore positively regulates and
initiates cell apoptosis.21,22 The function of BAD protein is regu
lated through its phosphorylation in some serine residues, in which
modulate its proteineprotein interactions and cellular localiza
tion.23 On the other hand, the caspase 8 is activated after the for
mation of death inducing signaling complex (DISC) and cleaves
different apoptotic proteins, resulting in execution of apoptosis.24
This caspase is involved in both extrinsic and intrinsic pathways
of apoptosis and acts via caspase 3 and Bid proteolytic cleavage. It
was indicated that caspase 8 is inactivated in many human cancers,
which may cause tumor progression and resistance to chemothera
peutics.25 On the basis of our results that showed downregulation of
BAD and CASP8 in ovarian tumoral samples compared to normal
tissues, we may explain that lack or decreased rates of Bad or
caspase 8 proteins in ovarian epithelial cells could possibly prevent
intrinsic and extrinsic apoptosis signaling pathways. Accordingly,
the decrease or resistance to apoptosis in epithelial ovarian cells
might be an important step in ovarian carcinogenesis.
In a previous study, it has been shown that overexpression of
BAD inhibits the growth of A549 lung adenocarcinoma cells
through inhibiting cell proliferation and inducing of apoptosis.21
Another study reported that reduction of BAD expression
by RNA interference leads to apoptosis prevention that suggests
integration of BAD in the antiapoptotic effects of EGFR and
PI3K pathways.26 The decreased levels of phosphorylated BAD
were shown during the development of hepatocellular tumorigenesis
as well, which propose its important role in apoptosis and cancer.27
In addition, other studies have shown the involvement of caspase 8
in ovarian apoptosis resistance. In a study on the ovarian cancer
cell line model of acquired cisplatin resistance, it was shown that
the increased caspase 8 protein level is involved in the initiation
of apoptosis via sensitivity to rhTRAIL induced apoptosis.28
Moreover, acquired rhTRAIL resistance in SW948 colon carci
noma cell line was shown to be caused by decreased ratio of
procaspase 8/c FLIP.29
Figure 1 The Expression of Proapoptotic Genes Between Tumor and Normal Adjacent Tissues. The Statistical Analysis of Data
Showed That the Expression of Two Genes, CASP8 and BAD, Has Signiﬁcantly Decreased in Tumoral Samples Compared to
Normal Adjacent Tissue Samples (P < .05)
Nasim Borhani et alAberrant methylation as a suppressor mechanism of gene tran
scription was frequently reported in promoter regions of tumor
suppressors in ovarian cancer.30 In this study, we investigated the
presence of DNA methylation in promoter regions of 2 genes, BAD
and CASP 8, in which their expressions were shown to be decreased
in tumoral samples compared to normal adjacent ovarian tissues.
First, we performed methylation sensitive enzyme HpaII and
following PCR to determine the possible methylation; then, the
MSP was carried out to conﬁrm our results. The results showed no
signiﬁcant DNA methylation in both investigated gene promoters.
Promoter hypermethylation in BAD gene was reported only in
myeloma,31 whereas methylation of CASP8 gene has been reportedFigure 2 HpaII-PCR for Analysis of BAD Gene Promoter Methylation
and Normal DNA Showed the Desired PCR Product; the T a
The PCR Following Digestion With HpaII Showed No Signi
Sample DNA (B). The PCR for CASP8 Gene Promoter on Intac
and No Ampliﬁcations After Digestion With HpaII (Wells 5frequently in many cancers.32 35 In a previous study on ovarian
cancer by Ozdemir et al.,30 it was reported that among 24 inves
tigated tumor suppressor genes, promoter methylation of 3 genes,
CDKN2B, CDH13, and RASSF1, was most frequent, and
methylation in CASP8 gene promoter reported very low in their
samples. In another study by Yang et al., it was shown that different
genes were methylated in 3 different gynecologic cancers: cervical,
endometrial, and ovarian cancers. The CASP8 gene was just
methylated in endometrial cancer and was not methylated in
ovarian cancer samples.36 Thus, our result is in agreement with
those previous observations that showed no signiﬁcant promoter
hypermethylation in CASP8 and BAD genes in ovarian cancer.Status. Polymerase Chain Reaction (PCR) on Undigested Tumoral
nd N Represent Tumoral and Normal Samples, Respectively (A).
ﬁcant Difference Between Tumoral (T) and Normal-Adjacent (N)
t and HpaII-Digested DNA Showed Desired Amplicons (Wells 1-4)
-8) (C)
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Figure 3 Methylation-Speciﬁc PCR for Analysis of CASP8 Gene Promoter Methylation Status. The UC and MC Represent Unmethylated
and Methylated Control DNA; UT and UN Represent Investigated Tumor and Normal Samples Using Unmethylated Speciﬁc
Primers; and MT and MN Represent Tumoral and Normal Samples Using Methylated Speciﬁc Primers. It Is Clear that There Is
No DNA Methylation Exist in CASP8 Gene Promoter in Ovarian Tumoral and Normal Samples
Down-Regulation of CASP-8 and BAD Genes in Ovarian Cancer
22 -Consequently, the signiﬁcant downregulation of these 2 genes
might be due to other mechanisms such as promoter mutations,
other epigenetic mechanisms, and/or upstream alterations of
transcription cascade activation. Taken together, our study showed
downregulation of BAD and CASP8 genes in ovarian cancer
tumoral samples compared to normal ovarian tissues, suggesting
the important role for these proapoptotic genes during ovarian
carcinogenesis.
Clinical Practice Points
What Is Already Known About This Subject?.
 Regarding our subject of study, it was previously shown that
caspase 8 gene is inactivated in many human cancers, and this
can lead to tumor progression and also causes resistance to
chemotherapeutics. Besides, it was reported that decreased level
of BAD expression in the cells using RNA interference can
prevent apoptosis.
What Are the New Findings?.
 Our ﬁndings showed downregulation of CASP8 and BAD genes
in tumoral ovarian samples versus normal ones that could lead to
decreased levels of Bad or caspase 8 proteins in ovarian epithelial
cells. Thereby, this shortcoming could possibly prevent or
decrease intrinsic and/or extrinsic apoptosis signaling pathways
and has possible roles in ovarian carcinogenesis.
How Might It Impact on Clinical Practice in the Foreseeable
Future?.
 The potential clinical impact of these types of ﬁndings from
clinical research into clinical practice needs conﬁrmatory studies
using wider population and functional studies both in vitro and
in animal models. The possible applications could be performing
gene therapy using vectors expressing these downregulated genes
to sensitize them to regular cell apoptosis or along with che
motherapies. In addition, expression proﬁling of different types
of tumors might have invaluable application in personal medi
cine for chemotherapies with less side effects. We believe that
this study will be a promising approach to cancer treatment.Acknowledgments
The authors thank Iran National Tumor Bank (INTB) personnel
for providing us the tumoral and normal samples.Clinical Ovarian and Other Gynecologic Cancer December 2014Disclosure
The authors have stated that they have no conﬂicts of interest.References
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010
Sep-Oct; 60:277-300.
2. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer
health disparities. Gynecol Oncol 2013 Apr; 129:258-64.
3. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol Endocrinol
2003 Oct 7; 1:68.
4. Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers 2007; 23:
397-410.
5. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer
2003 Apr; 3:243-52.
6. Matsushita H,Watanabe K, Yokoi T,Wakatsuki A. Unexpected ovarian malignancy
following laparoscopic excision of adnexal masses. Hum Reprod 2014, deu162.
7. Bogani G, Cromi A, Uccella S, et al. Laparoscopic versus vaginal hysterectomy for
benign indications in women aged 65 years or older: propensity-matched analysis.
Menopause 2014.
8. Barton CA, Hacker NF, Clark SJ, O’Brien PM. DNA methylation changes in
ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol
Oncol 2008 Apr; 109:129-39.
9. Kang S, Dong SM, Park NH. Frequent promoter hypermethylation of TGFBI in
epithelial ovarian cancer. Gynecol Oncol 2010 Jul; 118:58-63.
10. Campan M, Mofﬁtt M, Houshdaran S, et al. Genome-scale screen for DNA
methylation-based detection markers for ovarian cancer. PLoS One 2011; 6:e28141.
11. Ho CM, Huang CJ, Huang CY, Wu YY, Chang SF, Cheng WF. Promoter
methylation status of HIN-1 associated with outcomes of ovarian clear cell
adenocarcinoma. Mol Cancer 2012; 11:53.
12. Gao Y, Lou G, Zhang GM, et al. CHFR promoter hypermethylation and
reduced CHFR mRNA expression in ovarian cancer. Int J Biol Markers 2009 ; 24:
83-9.
13. Socha MJ, Said N, Dai Y, et al. Aberrant promoter methylation of SPARC in
ovarian cancer. Neoplasia 2009 Feb; 11:126-35.
14. Czekierdowski A, Czekierdowska S, Danilos J, et al. Microvessel density and CpG
island methylation of the THBS2 gene in malignant ovarian tumors. J Physiol
Pharmacol 2008 Sep; 59(Suppl 4):53-65.
15. Choi YL, Kang SY, Shin YK, et al. Aberrant hypermethylation of RASSF1A
promoter in ovarian borderline tumors and carcinomas. Virchows Arch 2006 Mar;
448:331-6.
16. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a
review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012 Dec;
45:487-98.
17. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis.
Nat Rev Cancer 2002 Apr; 2:277-88.
18. Portela A, Esteller M. Epigenetic modiﬁcations and human disease. Nat Biotechnol
2010 Oct; 28:1057-68.
19. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer
development and treatment response. Cancer Treat Rev 2008 Dec; 34:737-49.
20. Huang N, Zhu J, Liu D, et al. Overexpression of Bcl-2 Associated Death
Inhibits A549 Cell Growth In Vitro and In Vivo. Cancer Biother Radiopharm
2012; 27:164-8.
21. Huang N, Zhu J, Liu D, et al. Overexpression of Bcl-2-associated death
inhibits A549 cell growth in vitro and in vivo. Cancer Biother Radiopharm 2012
Mar; 27:164-8.
22. Huang Y, Liu D, Chen B, et al. Loss of Bad expression confers poor prognosis
in non-small cell lung cancer. Med Oncol 2012 Sep; 29:1648-55.
23. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regu-
lates BAD/Bcl-XL interaction and cell survival. J Biol Chem 2000 Aug 18; 275:
25865-9.
24. Duiker EW, van der Zee AG, de Graeff P, et al. The extrinsic apoptosis pathway and
its prognostic impact in ovarian cancer. Gynecol Oncol 2010 Mar; 116:549-55.
Nasim Borhani et al
25. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett 2009 Aug 28;
281:128-33.
26. She QB, Solit DB, Ye Q, O’Reilly KE, Lobo J, Rosen N. The BAD protein in-
tegrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in
PTEN-deﬁcient tumor cells. Cancer Cell 2005 Oct; 8:287-97.
27. Yoo NJ, Lee JW, Jeong EG, et al. Expressional analysis of anti-apoptotic phospho-
BAD protein and mutational analysis of pro-apoptotic BAD gene in hepatocellular
carcinomas. Dig Liver Dis 2006 Sep; 38:683-7.
28. Duiker EW, Meijer A, van der Bilt AR, et al. Drug-induced caspase 8 upregulation
sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
Br J Cancer 2011 Apr 12; 104:1278-87.
29. Van Geelen CM, Pennarun B, Ek WB, et al. Downregulation of active caspase 8 as
a mechanism of acquired TRAIL resistance in mismatch repair-proﬁcient colon
carcinoma cell lines. Int J Oncol 2010 Oct; 37:1031-41.
30. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation
of tumor suppressor genes in ovarian cancer. Exp Ther Med 2012 Dec; 4:
1092-6.31. Pompeia C, Hodge DR, Plass C, et al. Microarray analysis of epigenetic silencing
of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 2004
May 15; 64:3465-73.
32. Malekzadeh K, Sobti RC, Nikbakht M, et al. Methylation patterns of Rb1 and
Casp-8 promoters and their impact on their expression in bladder cancer. Cancer
Invest 2009 Jan; 27:70-80.
33. Bello MJ, De Campos JM, Isla A, Casartelli C, Rey JA. Promoter CpG methyl-
ation of multiple genes in pituitary adenomas: frequent involvement of caspase-8.
Oncol Rep 2006 Feb; 15:443-8.
34. Gonzalez-Gomez P, Bello MJ, Inda MM, et al. Deletion and aberrant
CpG island methylation of Caspase 8 gene in medulloblastoma. Oncol Rep 2004
Sep; 12:663-6.
35. Shivapurkar N, Toyooka S, Eby MT, et al. Differential inactivation of caspase-8 in
lung cancers. Cancer Biol Ther 2002 Jan-Feb; 1:65-9.
36. Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY. Differential DNA methylation
proﬁles in gynecological cancers and correlation with clinico-pathological data.
BMC Cancer 2006; 6:212.Clinical Ovarian and Other Gynecologic Cancer December 2014 - 23
